# Targeting NRF2 With Isoeugenol: A Promising Small Molecule for Neurodegenerative, Metabolic, and Chronic Inflammatory Disorders

## TL;DR

This paper reviews how isoeugenol, a compound from essential oils, may activate the NRF2 pathway to treat diseases caused by oxidative stress, such as neurodegenerative and metabolic disorders.

## Contribution

The paper provides a comprehensive analysis of isoeugenol's mechanisms for NRF2 activation and its therapeutic potential in oxidative stress-related diseases.

## Key findings

- Isoeugenol activates NRF2 through mechanisms like KEAP1 cysteine modification and glutathione depletion.
- It shows antioxidant, anti-inflammatory, and neuroprotective effects in preclinical models.
- The compound may help treat chronic diseases like diabetes and neurodegenerative disorders.

## Abstract

Oxidative stress, driven by an imbalance between oxidants and antioxidants, disrupts redox homeostasis and contributes to the development of chronic diseases, including cancer, diabetes, neurodegenerative disorders, and aging. The NRF2‐KEAP1 pathway is a pivotal cellular defense mechanism against oxidative stress, regulating the transcription of cytoprotective genes. Pharmacological NRF2 activation has emerged as a promising strategy to mitigate oxidative stress‐related pathologies; however, challenges regarding target specificity, pharmacodynamics, efficacy, and safety remain unresolved. Isoeugenol, a phenylpropanoid found in essential oils, has traditionally been recognized as a skin allergen but is now gaining attention for its potential as an NRF2 activator. Emerging evidence suggests that isoeugenol exerts antioxidant, anti‐inflammatory, and neuroprotective effects and modulates metabolic disorders such as diabetes mellitus. Despite its therapeutic potential, the direct correlation between isoeugenol’s effects and NRF2 activation remains underexplored. Existing studies indicate that isoeugenol may activate NRF2 through multiple mechanisms, including covalent modification of KEAP1 cysteine residues, increased AKT activation and GSK3β inactivation, and glutathione depletion leading to reactive oxygen species (ROS) generation. Understanding these activation pathways is critical for leveraging isoeugenol as a therapeutic agent. This review provides a comprehensive analysis of isoeugenol’s role in modulating NRF2 activity and its implications for treating oxidative stress‐driven diseases. By integrating current findings, this review highlights new insights into the therapeutic potential of isoeugenol in translational medicine. We propose future research directions to optimize its application in clinical settings, paving the way for more targeted and effective NRF2‐based interventions in chronic disease management.